Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00017121 · ClinicalTrials.gov registry record · Phase 1

Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung

A Phase 1 study of Metastatic Cancer and Melanoma (Skin), sponsored by Alliance for Clinical Trials in Oncology.

Completed
Registry status
Phase 1
Development phase
40
Enrollment target
20
Study locations

NCT00017121 is a Phase 1 study of Metastatic Cancer and Melanoma (Skin) that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 40 participants, below the 444-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00017121, a Phase 1 study of Metastatic Cancer and Melanoma (Skin), has completed, sponsored by Alliance for Clinical Trials in Oncology.

COMPLETED
Registry status
Phase 1
Development phase
40 participants
Enrollment target
20
Study locations

Study Summary

RATIONALE: Inhaling sargramostim may interfere with the growth of tumor cells and may be an effective treatment for melanoma that has spread to the lung. PURPOSE: This phase I trial is studying the side effects and best dose of inhaled sargramostim in treating patients with melanoma that is metastatic to the lung.

Conditions Studied

Metastatic Cancer Melanoma (Skin)

Interventions

  • BIOLOGICAL sargramostim

Study Locations (20)

Illinois

  • Rush-Copley Cancer Care Center - Aurora
  • St. Joseph Medical Center - Bloomington
  • Graham Hospital - Canton
  • Memorial Hospital - Carthage
  • Eureka Community Hospital - Eureka
  • Galesburg Clinic - Galesburg
  • Galesburg Cottage Hospital - Galesburg
  • Mason District Hospital - Havana
  • Hopedale Medical Complex - Hopedale
  • Joliet Oncology-Hematology Associates, Limited - West - Joliet
  • Kewanee Hospital - Kewanee
  • McDonough District Hospital - Macomb
  • BroMenn Regional Medical Center - Normal
  • Community Cancer Center - Normal
  • Community Hospital of Ottawa - Ottawa
  • Oncology Hematology Associates of Central Illinois, PC - Ottawa - Ottawa
  • Cancer Treatment Center at Pekin Hospital - Pekin
  • Proctor Hospital - Peoria

Arizona

  • Mayo Clinic Scottsdale - Scottsdale

Florida

  • Mayo Clinic - Jacksonville - Jacksonville

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2002-05
Est. Completion 2012-11
Phase Phase 1

Sponsor

Alliance for Clinical Trials in Oncology

446 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00017121

The ClinicalTrials.gov registry entry for NCT00017121 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 444-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (91% lower). The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Metastatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which sargramostim is the first listed.

NCT00017121 reports 20 study locations spanning 3 distinct geographic areas - top geographies include Illinois, Arizona, Florida.

Frequently Asked Questions

What is clinical trial NCT00017121 about?

NCT00017121 is a clinical study titled "Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung". RATIONALE: Inhaling sargramostim may interfere with the growth of tumor cells and may be an effective treatment for melanoma that has spread to the lung. PURPOSE: This phase I trial is studying the side effects and best dose of inhaled sargramostim in treating patients with melanoma that is metasta...

What is the current status of trial NCT00017121?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2002-05. Estimated completion is 2012-11.

What conditions does trial NCT00017121 study?

This clinical trial studies the following conditions: Metastatic Cancer, Melanoma (Skin).

What interventions are being tested in trial NCT00017121?

The interventions under investigation include: sargramostim (BIOLOGICAL).

Who is sponsoring clinical trial NCT00017121?

This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00017121 being conducted?

This trial has 20 study locations across Arizona, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Cancer

All registered trials for this condition

Melanoma (Skin)

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.